New combo therapy targets liver tumors in colorectal and lung cancer patients

NCT ID NCT04701476

Recruiting now Disease control Sponsor: Teclison Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 24, 2026 · Updated 2 times

Summary

This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver. The treatment combines a procedure that delivers a drug directly to liver tumors (TATE) with an immunotherapy drug (pembrolizumab) that helps the immune system fight cancer. The goal is to see if this combination can shrink tumors and help patients live longer. The study is for patients whose cancer has not responded to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER; LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Medical University Hsinchu Hospital
RECRUITING

Hsinchu, Taiwan

Contact Email: •••••@•••••
Chung Shan Medical University Hospital
RECRUITING

Taichung, Taiwan

Contact Email: •••••@•••••
University of California, Irvine Medical Center
RECRUITING

Orange, California, 92868, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER; LUNG CANCER